PATENT CLAIM ANALYSIS

Application Number: 15751610
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "217000"]

Abstract:
This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.

Claim (Index 2):
The method of  claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.18519
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14656031', '13579009', '14151106', '15851444', '13615085']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7238303343522441
- 35 USC 102 Novelty (BERT): 0.4986663982484992
- Combined Prediction Score: 0.7013139407418697
- Mean Citation Score: 156.706886
- Max Citation Score: 166.8717
- Similarity Product: 104.91556285554172

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test